XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

Stephanie B. Hatch, Lonnie P. Swift, Simona Caporali, Rebecca Carter, Esme J. Hill, Thomas P. Macgregor, Stefania D'Atri, Mark R. Middleton, Peter J. McHugh, Ricky A. Sharma

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection'. Together they form a unique fingerprint.

Medicine & Life Sciences